Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21420046 | 1.00 | POLB (0.40) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL26251001 | 1.00 | POLB (0.40) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL14487337 | 0.84 | LMNA (0.47) | TSHRGAAKDM4EALDH1A1HTT | |
| SCHEMBL21420050 | 0.81 | POLB (0.38) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL21420079 | 0.81 | POLB (0.38) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL20371748 | 0.81 | POLB (0.40) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL14555766 | 0.81 | POLB (0.40) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL14487355 | 0.81 | POLB (0.40) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL23793626 | 0.80 | CYP2C19 (0.40) | POLBCYP2C19MAPK1CYP2C9TSHR | |
| SCHEMBL25457871 | 0.80 | POLB (0.39) | POLBCYP2C19MAPK1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12594267-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| US-20240374598-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2024-11-14 | — | — | US | disclosed |
| US-20240376077-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4458415-A2 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | Gilead Sciences, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240316018-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240254104-A1 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | POLB 361/4885CYP2C19 564/4885MAPK1 3513/4885 |
| US-20240316018-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | SAP18, SLC11A2, CD4 | POLB 71/4885CYP2C19 3102/4885MAPK1 2482/4885 |
| US-12636279-B2 | Choline salt forms of an HIV capsid inhibitor | CHKA, SLC5A7, SLC44A1 | POLB 1952/4885CYP2C19 4825/4885MAPK1 1049/4885 |
| US-12594267-B2 | Capsid inhibitors for the treatment of HIV | CTDSP1, POLR2H, POLR2E | POLB 18/4885CYP2C19 2438/4885MAPK1 610/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | POLB 361/4885CYP2C19 564/4885MAPK1 3513/4885 |
| US-20240254104-A1 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | ZC3HAV1, GTF3C3, ZC3HAV1L | POLB 3024/4885CYP2C19 2870/4885MAPK1 2855/4885 |
| US-20240374598-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, SAMHD1, POLR2H | POLB 19/4885CYP2C19 3054/4885MAPK1 3523/4885 |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | ZC3HAV1, GTF3C3, ZC3HAV1L | POLB 3024/4885CYP2C19 2870/4885MAPK1 2855/4885 |
| US-20240376077-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | POLB 254/4885CYP2C19 2880/4885MAPK1 3679/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | POLB 1747/4885CYP2C19 386/4885MAPK1 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.